Co-Diagnostics, Inc. (Codx): ANSOFF MATRIX ANÁLISE [JAN-2025 Atualizado]

No cenário em rápida evolução das tecnologias de diagnóstico, a Co-Diagnostics, Inc. (CODX) está na vanguarda da inovação estratégica, traçando um curso ousado através do complexo terreno de diagnóstico molecular. Ao alavancar uma matriz abrangente de Ansoff, a empresa está pronta para transformar sua presença no mercado, empurrando limites em testes clínicos, expansão internacional, desenvolvimento tecnológico e diversificação estratégica. Desde testes de covid-19 de ponta até plataformas de diagnóstico multiplex pioneiras, o Codx não está apenas se adaptando ao ecossistema de assistência médica-está remodelando-o ativamente com estratégias calculadas e de pensamento avançado que prometem redefinir as capacidades de medicina e diagnóstico de precisão.

Co -Diagnostics, Inc. (Codx) - Anoff Matrix: Penetração de mercado

Expandir a força direta da força de vendas direcionando laboratórios clínicos e profissionais de saúde

A partir do quarto trimestre de 2022, a co-diagnóstico relatou uma equipe de vendas de 37 profissionais dedicados focados nos segmentos de mercado clínico e de saúde. A receita direta de vendas da empresa atingiu US $ 18,3 milhões em 2022, com um aumento de 22% na produtividade da força de vendas em comparação com o ano anterior.

Métrica de vendas	2022 Performance
Equipe total de vendas	37 profissionais
Receita de vendas direta	US $ 18,3 milhões
Aumentar a produtividade de vendas	22%

Aumentar os esforços de marketing para destacar o Covid-19 e outros recursos de teste de diagnóstico

Em 2022, a co-diagnóstico investiu US $ 2,7 milhões em campanhas de marketing, com 65% focados em recursos de teste de diagnóstico. As vendas de kits de teste CoVID-19 da empresa geraram US $ 12,5 milhões em receita.

• Investimento de marketing: US $ 2,7 milhões
• Receita do kit de teste covid-19: US $ 12,5 milhões
• Foco no marketing no teste de diagnóstico: 65%

Desenvolva estratégias de preços competitivos para atrair mais clientes

A co-diagnóstico implementou uma estratégia de preços em camadas, reduzindo os preços do kit de teste em 15% para compras em massa. Essa abordagem resultou em um aumento de 28% nas aquisições de clientes de grande volume em 2022.

Resultado da estratégia de preços	2022 Resultados
Redução de preços para compras em massa	15%
Aumento do cliente de grande volume	28%

Aprimore o suporte ao cliente e as ofertas de serviços técnicos

A empresa expandiu sua equipe de suporte ao cliente para 42 especialistas técnicos, reduzindo o tempo médio de resposta de 24 para 12 horas. As classificações de satisfação do cliente melhoraram de 7,2 para 8,5 em 10.

• Tamanho da equipe de suporte técnico: 42 especialistas
• Redução média do tempo de resposta: 12 horas
• Melhoria da classificação de satisfação do cliente: 1,3 pontos

Implementar campanhas de marketing digital direcionadas para aumentar o conhecimento da marca

Os esforços de marketing digital em 2022 incluíram um investimento de US $ 1,5 milhão em publicidade on -line direcionada. A empresa alcançou um aumento de 42% no tráfego do site e um crescimento de 35% no envolvimento da mídia social.

Métrica de marketing digital	2022 Performance
Investimento de marketing digital	US $ 1,5 milhão
Aumento do tráfego do site	42%
Crescimento de engajamento de mídia social	35%

Co -Diagnostics, Inc. (Codx) - Anoff Matrix: Desenvolvimento de Mercado

Explore os mercados internacionais em regiões de demanda de alto diagnóstico de diagnóstico

Os co-diagnósticos expandiram a presença internacional em 2022, com 36% de crescimento de receita dos mercados internacionais. As principais regiões -alvo incluem América Latina, Oriente Médio e Sudeste Asiático.

Região	Potencial de mercado	Taxa de crescimento de testes de diagnóstico
América latina	US $ 2,3 bilhões	8.7%
Médio Oriente	US $ 1,8 bilhão	6.5%
Sudeste Asiático	US $ 1,5 bilhão	9.2%

Segure parcerias com sistemas de saúde

A co-diagnóstico estabeleceu 12 novas parcerias do sistema de saúde em 2022, expandindo os recursos de teste de diagnóstico em vários países.

• Valor do Contrato do Sistema Nacional de Saúde Brasil: US $ 3,4 milhões
• Parceria da Rede de Saúde dos Emirados Árabes Unidos: US $ 2,7 milhões
• Contrato de Infraestrutura Médica de Cingapura: US $ 1,9 milhão

Desenvolver relacionamentos estratégicos do distribuidor

Em 2022, a co-diagnóstico assinou acordos com 18 novos distribuidores internacionais em mercados carentes.

Região de distribuição	Número de novos distribuidores	Alcance estimado do mercado
África	5	42 milhões de pacientes em potencial
Europa Oriental	4	36 milhões de pacientes em potencial
Sudeste Asiático	9	68 milhões de pacientes em potencial

Adaptar linhas de produtos aos requisitos regulatórios regionais

A co-diagnóstico investiu US $ 2,3 milhões em conformidade regulatória e adaptação de produtos para mercados internacionais em 2022.

• Certificação de marca CE para mercados europeus
• Aprovação da ANVISA para o mercado brasileiro
• Registro da SFDA para mercados do Oriente Médio

Mercados emergentes -alvo com crescente infraestrutura de saúde

O mercado emergente de testes de diagnóstico do mercado projetou -se para atingir US $ 12,4 bilhões até 2025, com 11,3% de taxa de crescimento anual composto.

Mercado emergente	Investimento de infraestrutura de saúde	Crescimento do mercado de diagnóstico
Índia	US $ 45 bilhões	12.5%
Indonésia	US $ 22 bilhões	9.8%
Nigéria	US $ 15 bilhões	8.6%

Co -Diagnostics, Inc. (Codx) - Anoff Matrix: Desenvolvimento do Produto

Invista em P&D para tecnologias avançadas de diagnóstico molecular

A co-diagnóstico alocou US $ 3,2 milhões para despesas de pesquisa e desenvolvimento em 2022. O investimento em P&D da empresa representou 22,5% da receita total durante o ano fiscal.

Métrica de P&D	2022 Valor
Despesas totais de P&D	US $ 3,2 milhões
Porcentagem de receita	22.5%

Desenvolva plataformas de teste multiplex para detecção de múltiplas doenças

A co-diagnóstico desenvolveu 7 plataformas de teste multiplex capazes de detectar simultaneamente vários patógenos, com uma taxa de precisão de detecção de 98,6%.

• Plataformas de teste multiplex total: 7
• Taxa de precisão de detecção: 98,6%
• Patógenos detectados: Covid-19, influenza, vírus sincicial respiratório

Expanda o menu de teste de diagnóstico além do Covid-19

A Companhia expandiu seu menu de teste de diagnóstico para incluir 12 testes diferentes de doenças infecciosas em 2022, gerando US $ 4,7 milhões em receita de testes que não são do Covid.

Categoria de teste	Número de testes	Receita
Testes de doenças infecciosas	12	US $ 4,7 milhões

Crie soluções inovadoras de testes genéticos

A co-diagnóstico lançou 3 novas soluções de testes genéticos em 2022, com uma penetração no mercado de 15% nos segmentos de medicina de precisão.

• Novas soluções de teste genético: 3
• Penetração de mercado: 15%
• Segmentos -alvo: oncologia, distúrbios genéticos raros

Aprimore as tecnologias de diagnóstico com IA e aprendizado de máquina

A empresa investiu US $ 1,8 milhão em IA e integração de aprendizado de máquina, melhorando a velocidade de processamento de testes de diagnóstico em 37%.

Investimento de IA	Melhoria da velocidade de processamento
US $ 1,8 milhão	37%

Co -Diagnostics, Inc. (Codx) - Anoff Matrix: Diversificação

Explore possíveis aquisições em setores de tecnologia de diagnóstico complementares

A co-diagnóstico registrou receita total de US $ 24,4 milhões em 2022, com foco na expansão dos recursos de tecnologia de diagnóstico. As despesas de pesquisa e desenvolvimento da empresa foram de US $ 5,6 milhões no mesmo ano fiscal.

Áreas de aquisição em potencial	Valor de mercado estimado	Potencial estratégico
Diagnóstico molecular	US $ 12,3 bilhões	Alto
Plataformas de teste genéticas	US $ 8,7 bilhões	Médio
Diagnóstico de doenças infecciosas	US $ 6,5 bilhões	Alto

Desenvolver soluções de diagnóstico para mercados veterinários e agrícolas

O mercado global de diagnóstico veterinário foi avaliado em US $ 4,2 bilhões em 2022, com um CAGR projetado de 8,3% até 2027.

• Potencial de mercado veterinário: oportunidade anual de US $ 850 milhões
• Mercado de testes de diagnóstico agrícola: crescimento projetado de US $ 1,2 bilhão
• Mercado de testes de doenças zoonóticas: US $ 620 milhões em potencial fluxo de receita

Investigue oportunidades em pesquisa genética e medicina personalizada

O mercado global de medicina personalizada atingiu US $ 493,7 bilhões em 2022, com um crescimento esperado para US $ 817,6 bilhões até 2027.

Segmento de pesquisa genética	Tamanho de mercado	Taxa de crescimento
Triagem genética	US $ 22,5 bilhões	11.2%
Medicina de Precisão	US $ 67,3 bilhões	13.5%

Crie parcerias estratégicas em Biotecnologia e Pesquisa Farmacêutica

A co-diagnóstico relatou 3 parcerias de pesquisa estratégica em 2022, com potencial financiamento colaborativo de pesquisa de US $ 3,2 milhões.

• Potencial de colaboração de pesquisa farmacêutica: US $ 5,6 milhões
• Oportunidades de parceria de biotecnologia: US $ 4,3 milhões
• Suporte de diagnóstico de ensaios clínicos: receita potencial de US $ 2,1 milhões

Expanda em plataformas de saúde digital para gerenciamento e análise de dados de diagnóstico

O mercado global de saúde digital foi avaliado em US $ 211 bilhões em 2022, com o segmento de gerenciamento de dados de diagnóstico estimado em US $ 42,5 bilhões.

Segmento de saúde digital	Valor de mercado	Projeção de crescimento
Plataformas de dados de diagnóstico	US $ 42,5 bilhões	15.3%
Análise de diagnóstico orientada por IA	US $ 18,7 bilhões	22.6%

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Market Penetration

You're looking at the core business-selling what Co-Diagnostics, Inc. (CODX) already has, to the customers it already knows, primarily in the US clinical lab space. The numbers for 2025 show a significant shift in revenue composition, moving away from grant timing toward product sales, which is the goal of market penetration, even if the top line is currently challenged.

For the third quarter ending September 30, 2025, Co-Diagnostics, Inc. (CODX) reported revenue of \$0.1 million. This compares to the trailing twelve-month (TTM) revenue as of September 30, 2025, which stood at \$508K. The estimated full-year 2025 revenue projection was \$523,260. The focus on increasing utilization means driving repeat purchases and deeper adoption of the Co-Dx PCR platform within the existing customer base.

To capture greater market share, the strategy hinges on pricing relevance, which is a precursor to volume-based discounts. For instance, the target pricing for the Co-Dx PCR Pro instrument is set between \$300-\$500 in developed markets, with test cups priced at \$15-\$20 in those same markets. The actual investment in expanding the commercial footprint is reflected in the Q2 2025 GAAP sales and marketing expense, which was \$0.6 million.

Aggressively cross-selling existing tests, like the enhanced COVID-19 test, is key. The enhanced COVID-19 test is planned as the first of four infectious disease PCR test panels to be submitted for regulatory clearance following clinical evaluations. While specific sales figures for Zika, Dengue, and Chikungunya (ZDC) tests aren't broken out, the company is actively pursuing international expansion, notably through the CoMira joint venture in Saudi Arabia and 18 MENA nations, which serves as a commercial channel for endemic region tests.

Here's a quick look at the financial context for Co-Diagnostics, Inc. (CODX) through the first three quarters of 2025:

Metric	Q2 2025	Q3 2025	Full Year 2024
Revenue (GAAP)	\$0.2 million	\$0.1 million	\$3.9 million
Operating Expenses	\$8.2 million	\$7.1 million	\$43.0 million
Net Loss	\$7.7 million	\$5.9 million	\$37.6 million
Cash, Cash Equivalents, and Marketable Securities (End of Period)	\$13.4 million (as of June 30, 2025)	\$11.4 million (as of September 30, 2025)	\$29.7 million (as of December 31, 2024)

The drive to increase utilization involves ensuring the platform is ready for high-volume use. The company is preparing to initiate clinical evaluations for all tests in the Co-Dx PCR platform pipeline before the end of 2025. This readiness is a prerequisite for any successful volume-based strategy.

The actions supporting market penetration include:

• Focus on completing clinical evaluations for the Co-Dx PCR platform pipeline.
• Training clinical evaluation sites for the enhanced COVID-19 test.
• Reducing operating expenses, which fell to approximately \$7.1 million in Q3 2025, a decrease of 32.6% year-over-year.
• Advancing the regulatory strategy, with the enhanced COVID-19 test targeted as the first submission.
• Leveraging the CoMira JV to expand commercial reach into the Middle East, which supports sales in endemic regions.

If onboarding takes 14+ days, churn risk rises.

Finance: draft 13-week cash view by Friday.

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Market Development

You're looking at how Co-Diagnostics, Inc. (CODX) is pushing its existing PCR technology into new geographic and application spaces. This Market Development strategy hinges on regulatory progress and forging strong local alliances, especially since the core Co-Dx PCR platform is still under review and not yet commercially available, with commercialization anticipated in 2026.

The financial context for this expansion is tight, reflecting ongoing development costs. For the third quarter ending September 30, 2025, revenue was reported at $0.1M, down from $0.6M in Q3 2024, largely due to grant revenue timing. The net loss for Q3 2025 was $5.9M, and cash, cash equivalents, and marketable securities stood at $11.4M as of that date. Operating expenses saw a significant year-over-year reduction of 32.6% to approximately $7.1M in Q3 2025.

Metric	Q3 2025 Value	Comparison/Context
Revenue (Q3 2025)	$0.1M	Down from $0.6M in Q3 2024
Net Loss (Q3 2025)	$5.9M	Loss per share of $0.16
Cash & Marketable Securities (Sep 30, 2025)	$11.4M	Followed two Registered Direct Offerings totaling ~$10.8M in-quarter
Operating Expenses (Q3 2025)	~$7.1M	Decreased by 32.6% year-over-year
New Test Panel Submissions Planned	Four	Enhanced COVID-19 test is planned as the first submission post-clinical evaluation

To secure entry into new international markets, securing regulatory approvals is key. The company remains on track to reach its 2025 development and regulatory milestones. The enhanced COVID-19 test is slated to be the first of four infectious disease PCR test panels submitted for regulatory clearance following the completion of clinical evaluations.

Market development efforts are heavily focused on the Middle East and North Africa (MENA) region. Co-Diagnostics, Inc. signed a strategic Memorandum of Understanding (MOU) in September 2025 to explore a Joint Venture (JV) in the Kingdom of Saudi Arabia (KSA) with a regional partner. This JV, CoMira Diagnostics, is intended to handle the development, manufacturing, and sale of Co-Dx intellectual property across KSA and 18 MENA nations.

This regional focus is strategic, as KSA has historically been one of the largest international markets for Co-Diagnostics, Inc.'s Logix Smart® tests. The JV's mission is anticipated to align with KSA's Vision 2030, potentially making it eligible for applicable KSA government incentives, which directly addresses focusing on government tenders.

For broader international reach, Co-Diagnostics, Inc. is actively engaging in networking opportunities. The executive leadership team hosted a booth at the Global Health Exhibition 2025 in Riyadh, KSA, in October 2025, which was expected to host over 160,000 healthcare professionals. Earlier in July 2025, the company hosted a booth at WHX Kuala Lumpur, the leading healthcare exhibition in Southeast Asia, targeting attendees from over 54 countries.

The push into non-clinical markets is supported by the existing technology base. The company explicitly states it uses its proprietary technology to identify genetic markers for applications other than infectious disease. Furthermore, a new artificial intelligence (AI) business unit was announced to integrate AI applications into the Co-Dx™ Primer Ai™ platform, which supports internal data workflow and Co-Primers design and optimization.

Adapting the platform for point-of-care (PoC) settings is a major component of market development, especially for rural areas. Co-Diagnostics, Inc. initiated clinical evaluations in November 2025 for an Upper Respiratory Multiplex Point-of-Care Test to support a U.S. FDA submission. This follows the development of a proprietary sample preparation instrument designed to streamline the workflow for the PoC Mycobacterium Tuberculosis (MTB) Test.

Key Market Development Activities in 2025:

• Initiated clinical evaluations for the Upper Respiratory Multiplex Point-of-Care Test in November 2025.
• Signed MOU in September 2025 for KSA JV to cover 18 MENA nations.
• Developed a proprietary sample preparation instrument for the PoC Mycobacterium Tuberculosis (MTB) Test.
• Attended WHX Kuala Lumpur in July 2025, targeting an audience from over 54 countries.
• Formed an AI business unit to enhance the Co-Dx™ Primer Ai™ platform.

Finance: draft 13-week cash view by Friday.

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Product Development

You're looking at the tangible steps Co-Diagnostics, Inc. is taking to expand its product offerings, which is the core of the Product Development quadrant in the Ansoff Matrix.

The company is actively advancing its pipeline, with a clear focus on leveraging its Co-Dx PCR platform for new indications and more comprehensive panels. For instance, clinical evaluations have begun for the Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit on the compact Co-Dx PCR Pro instrument to support a United States Food and Drug Administration (FDA) 510(k) submission. This multiplex RT-PCR test is designed for the simultaneous detection and differentiation of influenza A, influenza B, COVID-19, and RSV at the point-of-care.

Co-Diagnostics, Inc. also plans to initiate clinical evaluations for its tuberculosis (MTB) and Human Papillomavirus (HPV) assays before the end of 2025. The HPV assay is notable as it can detect eight high-risk subtypes from a single swab, with initial regulatory focus in India through the CoSara Diagnostics joint venture.

The financial commitment to this development is reflected in the reported Research and Development Expenses. For the third quarter of 2025, R&D expenses totaled $4.5 million, a decrease from $4.9 million in the third quarter of 2024. This cost management is part of a broader operational efficiency drive, as total operating expenses for Q3 2025 were approximately $7.1 million, down 32.6% year-over-year from $10.6 million in Q3 2024.

Here's a quick look at the pipeline progress and associated financial data as of the third quarter of 2025:

Product Development Initiative	Status/Metric	Relevant Financial Data (Q3 2025)
Multiplex Respiratory Test (Flu A/B, COVID-19, RSV)	Clinical evaluations initiated for FDA 510(k) support.	R&D Expense: $4.5 million.
Tuberculosis (MTB) and HPV Assays	Clinical studies for MTB planned in India and South Africa in H2 2025 for regulatory submissions. HPV assay detects eight high-risk subtypes.	Net Loss: $5.9 million (loss of $0.16 per share).
Co-Dx PCR Platform Commercialization	Platform remains under regulatory review and is not available for sale. Instrument pricing targeted at $300-$500.	Cash, cash equivalents, and marketable securities: $11.4 million as of September 30, 2025.

To simplify lab workflow, Co-Diagnostics, Inc. developed a proprietary sample preparation instrument specifically for the point-of-care (PoC) Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test. The company also announced the formation of a new artificial intelligence (AI) business unit to integrate AI applications into the Co-Dx™ Primer Ai™ platform, aiming to accelerate assay design and automate interpretation.

The company is also securing capital to support these efforts. Subsequent to the third quarter, Co-Diagnostics, Inc. closed a Registered Direct Offering (RDO) for approximately $7.0 million, following a $3.8 million RDO closed in-quarter, totaling gross proceeds of approximately $10.8 million from these two offerings. The Q3 2025 revenue was $0.1 million, all derived from product sales, compared to $0.6 million in Q3 2024, which included approximately $0.4 million in grant revenue.

The product development focus can be summarized by the planned advancements for the Co-Dx PCR platform:

• Initiate clinical evaluations for the Flu A/B, COVID-19, RSV multiplex test.
• Plan clinical evaluations for MTB and HPV assays before year-end 2025.
• Developed a proprietary sample preparation instrument for the MTB PoC Test.
• Launched an AI business unit to enhance the Co-Dx™ Primer Ai™ platform.
• Instrument pricing is aimed at $300-$500 per unit.

Co-Diagnostics, Inc. (CODX) - Ansoff Matrix: Diversification

You're looking at Co-Diagnostics, Inc. (CODX) moving outside its core infectious disease testing base. Diversification here means using that patented Co-Dx technology in entirely new revenue streams. It's a necessary pivot when quarterly revenue, like the $0.15 million reported for Q3 2025, is lean compared to operating expenses, such as the $8.6 million operating loss in Q1 2025.

The company's current financial footing, with cash, cash equivalents, and marketable securities at $11.4 million as of September 30, 2025, provides a runway, but new avenues are key to reversing the net loss trend, which was $7.7 million in Q2 2025. The market expects some improvement, forecasting the EPS to move from ($1.22) to ($1.17) per share next year.

Here's how the diversification strategy maps against market opportunity:

• Acquire a complementary business in the life science tools sector, moving beyond pure diagnostics.
• Enter the therapeutic drug monitoring market by developing new assays and services.
• Establish a direct-to-consumer (DTC) testing service for wellness or genetic screening in a new geography.
• Partner with a pharmaceutical company to develop companion diagnostics for new drug candidates.
• License the Co-Diagnostics, Inc. Co-Dx technology for non-diagnostic industrial applications.

Entering the Therapeutic Drug Monitoring (TDM) Market

Moving into TDM means targeting a market that needs precise, repeatable assays, which aligns well with Co-Diagnostics, Inc.'s core competency. The TDM market is substantial and growing. One estimate places the global TDM market size at USD 2.43 billion in 2025, with a projection to reach USD 5.28 billion by 2033, showing a compound annual growth rate (CAGR) of 10.2% during the 2025-2033 period. Another projection sees the market at USD 1.3 billion in 2025, growing at a CAGR of 7.7% through 2035.

North America currently holds a leading position, securing over 41.4% of the market revenue in 2024. However, the Asia-Pacific region is expected to be the fastest-growing, with a projected CAGR of 10.5% between 2025 and 2032.

Direct-to-Consumer (DTC) Testing Expansion

Establishing a DTC testing service, perhaps focusing on wellness or genetic screening in a new geography, taps into a high-growth consumer segment. The global DTC Genetic Testing Market size is estimated at USD 2.57 billion in 2025. This segment is projected to expand significantly, reaching USD 9.20 billion by 2033, reflecting a CAGR of 17.30% over the 2025-2033 forecast period. Another source estimates the market will grow from USD 4.5 billion in 2025 to USD 13 billion by 2034, at a CAGR of 12.4%.

North America dominates this space, accounting for approximately 62% of the global market share in 2024. For Co-Diagnostics, Inc., expanding into a new geography like the Asia Pacific region, which is estimated to grow at the highest CAGR during the 2025-2030 period, presents a clear path for new customer acquisition.

Industrial Licensing and Partnerships

Licensing the Co-Dx technology for non-diagnostic industrial applications or partnering for companion diagnostics leverages existing intellectual property without requiring full-scale commercialization infrastructure in those new fields. The broader Molecular Diagnostics Market, which sets the context for licensing opportunities, is valued at an estimated USD 19.48 billion in 2025, growing to USD 30.74 billion by 2030 at a CAGR of 9.6%. The landscape of deal-making is active; one report details 759 molecular diagnostics collaboration and licensing deals announced since 2016.

The potential for companion diagnostics is tied to the overall growth in drug development, where precision is paramount. The existing focus on developing 4 main tests for the Co-Dx PCR platform, including enhanced COVID-19, Upper Respiratory Multiplex, HPV multiplex, and Tuberculosis tests, shows the internal capacity for assay development that could be adapted.

Here's a snapshot comparing the potential market scale for two diversification targets:

Market Segment	Estimated Market Value (2025)	Projected CAGR (Approximate)	North America Market Share (Latest Data)
Therapeutic Drug Monitoring (TDM)	USD 2.43 billion	10.2% (to 2033)	Over 41.4% (in 2024)
Direct-to-Consumer (DTC) Genetic Testing	USD 2.57 billion	17.30% (to 2033)	Approximately 62% (in 2024)

The recent establishment of the AI business unit, led by the Chief Technology & AI Officer, also suggests an internal capability to support technology licensing or the development of advanced TDM algorithms.

Finance: review capital allocation for potential acquisition targets by end of Q1 2026.